{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:00:59Z","timestamp":1780977659627,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107215","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:42:05Z","timestamp":1777272125000},"page":"107215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world outcomes of cladribine in people \u226555 years of age with multiple sclerosis"],"prefix":"10.1016","volume":"111","author":[{"given":"Kyle","family":"Smoot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamela","family":"Stuchiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Gervasi-Follmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiayi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107215_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.122913","article-title":"Disease-modifying therapy use and health resource utilisation associated with multiple sclerosis over time: a retrospective cohort study from Alberta, Canada","volume":"458","author":"Balcom","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.msard.2026.107215_bib0014","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1177\/13524585241272938","article-title":"Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations","volume":"30","author":"Coerver","year":"2024","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2026.107215_bib0005","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107215_bib0006","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40120-024-00603-y","article-title":"Narrative review on the use of cladribine tablets as exit therapy for stable elderly patients with Multiple sclerosis","volume":"13","author":"de Seze","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2026.107215_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103490","article-title":"Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years","volume":"58","author":"Disanto","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107215_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104757","article-title":"The importance of the patient\u2019s perspective in decision-making in multiple sclerosis: results of the OwnMS patient perspectives study","volume":"75","author":"Florio-Smith","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107215_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578368","article-title":"As time goes by: treatment challenges in elderly people with multiple sclerosis","volume":"391","author":"Gelibter","year":"2024","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.msard.2026.107215_bib0007","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2026.107215_bib0010","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2026.107215_bib0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11910-024-01333-2","article-title":"The impact of aging on multiple sclerosis","volume":"24","author":"Goyne","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2026.107215_bib0026","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","article-title":"Ageing and multiple sclerosis","volume":"22","author":"Graves","year":"2023","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107215_bib0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200415","article-title":"The Italian multiple sclerosis register experience with cladribine: impact on relapses, PIRA, and treatment sequencing strategies evaluation","volume":"12","author":"Guerra","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2026.107215_bib0012","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2023.2125","article-title":"Initiation patterns of disease-modifying therapies for multiple sclerosis among US adults and children, 2001 through 2020","volume":"80","author":"Henderson","year":"2023","journal-title":"JAMa Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.107215_bib0021","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/jnnp-2017-317411","article-title":"Cladribine: mechanisms and mysteries in multiple sclerosis","volume":"89","author":"Jacobs","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2026.107215_bib0023","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awac237","article-title":"Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions","volume":"146","author":"Joly","year":"2023","journal-title":"Brain"},{"issue":"Pt 12","key":"10.1016\/j.msard.2026.107215_bib0019","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1093\/brain\/awt281","article-title":"Sex as a determinant of relapse incidence and progressive course of multiple sclerosis","volume":"136","author":"Kalincik","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107215_bib0015","article-title":"Switching from anti-CD20 therapies to cladribine and vice versa - analysis of a German relapsing multiple sclerosis cohort","author":"Konen","year":"2025","journal-title":"Neurotherapeutics."},{"issue":"1","key":"10.1016\/j.msard.2026.107215_bib0008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2026.107215_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110576","article-title":"Age-associated alterations in immune function and inflammation","volume":"118","author":"Lewis","year":"2022","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"13","key":"10.1016\/j.msard.2026.107215_bib0022","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.msard.2026.107215_bib0004","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/advances\/nmy035","article-title":"Perspective: should vitamin E recommendations for older adults Be increased?","volume":"9","author":"Meydani","year":"2018","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.msard.2026.107215_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123727","article-title":"Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: a real-world study","volume":"478","author":"Piedrabuena","year":"2025","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2026.107215_bib0024","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s13365-017-0561-9","article-title":"Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy","volume":"23","author":"Prosperini","year":"2017","journal-title":"J. Neurovirol."},{"issue":"12","key":"10.1016\/j.msard.2026.107215_bib0018","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"UBCMS Clinic Neurologists. Relapses in multiple sclerosis are age- and time-dependent","volume":"79","author":"Tremlett","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2026.107215_bib0028","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107215_bib0013","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"10","key":"10.1016\/j.msard.2026.107215_bib0002","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology."},{"issue":"14","key":"10.1016\/j.msard.2026.107215_bib0001","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2026.107215_bib0029","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:42:33Z","timestamp":1780976553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826002518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"alternative-id":["S2211034826002518"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107215","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of cladribine in people \u226555 years of age with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107215"}}